A new study in JAMA Open Network found that, when brand drug manufacturers raise their list prices, commercially insured patients with deductibles and coinsurance do not directly benefit from the secret rebates the manufacturers pay insurance companies and PBMs. | Shutterstock

Study: Patients with Deductibles and Coinsurance Pay More When a Drug’s List Price Rises

Commercially insured patients with deductibles and coinsurance pay more when manufacturers raise a drug’s list price and do not directly benefit from the confidential rebates paid by manufacturers to insurers, according to a study published this morning in JAMA Open Network.

The study was authored by clinicians affiliated with Brigham & Women’s Hospital and the Harvard School of Medicine. They examined how list and net prices changed for 79 brand name drugs that sold more than 1,000 units per quarter between 2015 and 2017. Although small in number, those drugs generated $67 billion in sales revenue in 2017, or nearly 15% of all expenditures on prescription drugs in the U.S.

Commercially insured patients with deductibles and coinsurance pay more when manufacturers raise a drug’s list price and do not directly benefit from the confidential rebates paid by manufacturers to insurers, according to a study published this morning in JAMA Open Network.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer